BMY Chart

1 Month

	Date	Diff
	2025-05-02	+1.94 %
Bristol-Myers Squibb's stock (BMY) rose 1.94% and reached a new 52-week high due to insider buying activity and positive earnings results that exceeded analyst expectations. The increase in stock price was influenced by the acquisition of shares by EVP Samit Hirawat, who bought a significant number of shares, indicating confidence in the company's future, along with favorable analyst ratings and robust earnings performance. Bristol Myers Squibb (BMY) stock rose by 1.94% following positive results from a phase I clinical trial evaluating its monoclonal antibody, AMG 404, which demonstrated safety, tolerability, and promising preliminary antitumor activity in patients with advanced solid tumors.
	2025-04-29	+1.57 %
Bristol-Myers Squibb (BMY) stock rose 1.57% as analysts' earnings forecasts were lowered, yet the company reported higher-than-expected earnings and revenue for the recent quarter, indicating strong operational performance that likely bolstered investor confidence. Bristol Myers Squibb (BMY) stock rose 1.57% following the company's announcement of better-than-expected first-quarter results and an upward revision of its full-year revenue and profit forecasts, which boosted investor confidence despite a year-over-year revenue decline. Bristol Myers Squibb (BMY) stock increased by 1.57% likely due to positive investor sentiment related to its collaboration with Purple Biotech on cancer therapies, highlighting confidence in its oncology pipeline and potential for long-term growth.
	2025-04-28	+1.17 %
Bristol-Myers Squibb (BMY) stock rose by 1.17% due to stronger-than-expected quarterly earnings reported on April 24, 2025, which exceeded analysts' estimates and indicated robust revenue growth, despite a downgrade in future EPS projections by a research firm. Bristol-Myers Squibb (BMY) stock rose 1.17% last night, likely due to strong institutional ownership, improving market sentiment towards biopharmaceuticals, and its diverse portfolio of products addressing multiple medical conditions, despite facing competition from companies like CalciMedica, which may show greater short-term upside in stock price. Bristol-Myers Squibb (BMY) stock rose by 1.17% following positive quarterly earnings that exceeded analysts' estimates, reinforcing a stable outlook with earnings forecasts and maintaining a consensus "Hold" rating amidst mixed price target revisions from various investment firms.
	2025-04-25	-1.62 %
Bristol-Myers Squibb (BMY) stock declined by 1.62% following a reaffirmed neutral rating by Cantor Fitzgerald with a target price of $55.00, despite reporting better-than-expected quarterly earnings, indicating market concerns about its future growth prospects and investor sentiment. Bristol-Myers Squibb (BMY) stock dropped 1.62% following Cantor Fitzgerald's F2025 earnings per share estimates of $6.81, which were slightly below the consensus estimate of $6.74, and amidst varying price target adjustments and ratings from several analysts. Bristol-Myers Squibb (BMY) stock fell by 1.62%, reaching $48.33, primarily due to fluctuations in trading volume and broader market trends impacting pharmaceutical stocks, as indicated by divergence in recent stock performance among major competitors like Eli Lilly, Johnson & Johnson, and Pfizer. Bristol-Myers Squibb (BMY) stock fell by 1.62% after Jefferies Financial Group lowered its price target from $70.00 to $68.00, leading to a gap down in share price before the market opened.
	2025-04-24	+0.33 %
Bristol-Myers Squibb (BMY) stock rose 0.33% likely due to anticipation of positive quarterly earnings and revenue expectations, with analysts forecasting earnings of $1.49 per share on $10.70 billion in revenue. Bristol Myers Squibb (BMY) stock rose by 0.33% following the company's strong quarterly earnings report and its raised revenue projections. The increase in BMY's stock price is attributed to the positive earnings announcement, which likely boosted investor confidence in the company's financial outlook. Bristol Myers Squibb stock rose by 0.33% after it beat first-quarter expectations and raised its annual outlook, despite experiencing a decline over the previous two days. Bristol Myers Squibb (BMY) stock rose 0.33% after the company reported stronger-than-expected first-quarter 2025 revenues of $11.20 billion and raised its fiscal year adjusted EPS and sales guidance, indicating robust performance, particularly from its Growth Portfolio, despite some declines in specific drug sales. Bristol Myers Squibb's stock rose 0.33% following its earnings report, which showed better-than-expected revenue despite a decline, indicating strength amidst ongoing concerns. The stock's increase can be attributed to the company's earnings beating forecasts and a positive outlook, even though revenue decreased compared to the previous year.
	2025-04-23	-2.59 %
Bristol Myers Squibb (BMY) stock fell by 2.59% due to historical patterns indicating a tendency for negative reactions following earnings announcements, with traders potentially anticipating a similar outcome ahead of its upcoming earnings report on April 24, 2025. Bristol-Myers Squibb (BMY) stock fell by 2.59% despite receiving an overweight rating and a price target increase from various analysts, likely due to market volatility and mixed investor sentiment reflected in the stock's consensus hold rating. Bristol Myers Squibb's stock (BMY) dropped by 2.59% following the release of topline results from the Phase 3 ARISE trial, which evaluated the efficacy and safety of their drug Cobenfy, indicating it did not meet expectations or show significant promise in treating inadequately controlled symptoms in adults. Bristol-Myers Squibb's stock (BMY) fell by 2.59% amid concerns about the looming risk of a recession in the U.S., which may be affecting investor confidence.
	2025-04-22	+1.8 %
Bristol-Myers Squibb (BMY) stock rose 1.8% despite being down 11% year-to-date, as the company is working through patent challenges and has made significant acquisitions, like MyoKardia for its HCM drug Camzyos, which may positively influence investor sentiment.
	2025-04-17	-0.26 %
Bristol-Myers Squibb (BMY) stock fell 0.26% due to a reduction in Q1 2025 earnings per share estimates by William Blair, leading to concerns about the company's financial outlook. Bristol-Myers Squibb (BMY) stock saw a decline of 0.26% likely due to market anticipation ahead of its upcoming quarterly earnings report and analysts' mixed ratings impacting investor sentiment.
	2025-04-16	-1.28 %
Bristol Myers Squibb (BMY) stock declined by 1.28% amid broader concerns about impending Medicaid cuts that could negatively impact healthcare companies' revenues, particularly those dependent on low-income patient coverage.
	2025-04-15	-2.61 %
Bristol-Myers Squibb (BMY) stock fell by 2.61% due to potential concerns regarding competition and market conditions as the pharmaceutical industry increasingly looks towards China for drug opportunities. Bristol Myers Squibb (BMY) stock fell by 2.61% following the announcement that its Phase 3 ODYSSEY-HCM trial of Camzyos failed to meet its dual primary endpoints for treating non-obstructive hypertrophic cardiomyopathy.
	2025-04-14	+1.24 %
Bristol Myers Squibb's stock experienced a 1.24% increase despite a recent setback with its heart drug, Camzyos, which negatively affected Cytokinetics; the rise in BMY stock is likely attributed to broader market factors or investor optimism rather than the performance of the drug. Bristol-Myers Squibb (BMY) stock rose 1.24% despite a price target reduction by UBS, likely influenced by positive quarterly earnings results and ongoing analyst interest, with various ratings indicating a generally stable outlook for the company.
	2025-04-10	-6.1 %
Bristol-Myers Squibb (BMY) stock fell by 6.1% following the recent sale of shares by Representative Greg Landsman, which may have influenced investor sentiment and contributed to the decline.
	2025-04-04	-4.36 %
Bristol-Myers Squibb (BMY) stock fell by 4.36% due to revised Q1 2027 earnings per share estimates from Zacks Research, which lowered forecasts from $1.35 to $1.34, signaling concerns about the company's future earnings performance.
	2025-04-02	+0.08 %
Bristol Myers Squibb (BMY) stock saw a slight increase of 0.08% likely due to its upcoming dividend payment, which is positively perceived by investors.
	2025-04-01	-2.36 %
Bristol Myers Squibb (BMY) stock fell by 2.36% despite a 4% year-to-date increase, likely due to broader market volatility affecting investor sentiment.
	2025-03-31	+1.62 %
Bristol Myers Squibb (BMY) stock rose 1.62% due to overall positive market sentiment, even as concerns about potential tariff impacts on pharmaceutical products loom.
	2025-03-28	+1.9 %
Bristol-Myers Squibb (BMY) stock rose by 1.9% as investors are shifting their focus back to stable, dividend-paying companies amid tariff uncertainties and declining momentum in AI stocks, making it an attractive investment option in the current turbulent market. Bristol-Myers Squibb (BMY) stock rose 1.9% largely due to positive analyst upgrades, including Jefferies Financial Group raising their rating to "buy" and increasing the target price, along with other firms setting higher price targets, which indicates improved investor confidence and market sentiment.
	2025-03-27	-0.52 %
Bristol-Myers Squibb (BMY) stock fell by 0.52% amid a consensus "Hold" rating from analysts, with mixed performance forecasts leading to investor uncertainty. Bristol Myers Squibb (BMY) stock recently dropped by 0.52%, potentially due to investor reactions to broader market dynamics or company-specific factors, despite the positive news regarding the European Commission's approval of their CAR T cell therapy, Breyanzi.
	2025-03-26	+0.03 %
The article discusses Bristol Myers Squibb (BMY) stock's slight increase of 0.03%, likely driven by positive developments in clinical trials and partnerships, particularly its collaboration with Perspective Therapeutics, which is advancing innovative cancer treatment therapies that may enhance BMY's market position and growth prospects.
	2025-03-25	-3.05 %
Bristol Myers Squibb (BMY) stock fell by 3.05% primarily due to increasing fears regarding government regulations on the pharmaceutical industry, as there is growing concern that such regulations could adversely affect profit margins and operational practices within companies like BMY.
	2025-03-24	-0.03 %
Bristol Myers Squibb (BMY) stock slipped 0.03% despite a strong six-month performance, rising over 23%, potentially due to market fluctuations or profit-taking by investors.
	2025-03-14	-2.11 %
Bristol-Myers Squibb (BMY) stock declined by 2.11% following a generally mixed sentiment among analysts, with varying earnings estimates and recent shifts in institutional investor positions, which may have affected investor confidence.
	2025-03-13	+0.79 %
Bristol-Myers Squibb (BMY) stock rose by 0.79% following an upgrade in earnings per share estimates by William Blair, signaling positive performance expectations from analysts and the company exceeding previous earnings consensus.
	2025-03-11	-2.54 %
Bristol Myers Squibb (BMY) stock fell by 2.54% following concerns surrounding its acquisition of 2seventy bio, Inc., as there are ongoing investigations into whether 2seventy bio's Board acted in the best interest of its shareholders and provided fair value in the deal.
	2025-03-10	+3.31 %
Bristol-Myers Squibb (BMY) stock increased by 3.31% due to its strong revenue growth, particularly in its Growth Portfolio, consistent dividend payments, and investors seeking stability in an uncertain macroeconomic landscape that favors defensive strategies like dividend stocks.
	2025-03-05	+0.64 %
Bristol Myers Squibb (BMY) stock rose by 0.64% recently, driven by its strong Q4 performance and investor shifts towards defensive positions amid economic uncertainty, despite facing long-term challenges from declining legacy drug sales and impending competition.
	2025-03-03	+0.42 %
Bristol Myers Squibb's (BMY) stock rose by 0.42% due to the company winning an award for its impactful advertising campaign promoting a new schizophrenia drug, emphasizing the need for more authentic conversations around mental health topics in media.
	2025-02-27	+2.47 %
Bristol-Myers Squibb (BMY) stock rose 2.47% following positive analyst upgrades, including increased price targets and favorable earning reports, indicating stronger financial performance and investor confidence. Bristol-Myers Squibb (BMY) stock rose 2.47% due to increased call option trading and insider purchases, as well as positive analyst ratings that reflect a bullish sentiment toward the company's future performance.
	2025-02-25	+0.57 %
Bristol-Myers Squibb (BMY) stock rose 0.57% following analysts’ revisions of their earnings estimates and a positive quarterly earnings report that exceeded expectations, alongside increased institutional investment and a recent dividend increase.
	2025-02-20	+1.47 %
Bristol Myers Squibb (BMY) stock rose by 1.47% due to its strong appeal as a leading drug stock, as highlighted by Jim Cramer, who considers it one of the most attractive options in the pharmaceutical industry.
	2025-02-19	+1.01 %
Bristol-Myers Squibb (NYSE:BMY) stock rose 1.01% last night, driven by positive earnings results that surpassed analyst expectations, a recent increase in its quarterly dividend, and significant interest from institutional investors who have been buying and holding shares of the company.
	2025-02-12	+0.38 %
Bristol-Myers Squibb (BMY) stock rose by 0.38% due to positive earnings estimates and upgrades from several analysts, including an EPS beat in their latest quarterly results, indicating strong performance and investor confidence in the company's future profitability. The article discusses Bristol-Myers Squibb's (BMY) stock performance, highlighting a recent increase of 0.38%, which is attributed to positive sentiments about its groundbreaking drug COBENFY for schizophrenia, alongside praise from Jim Cramer who encourages investors to buy more of the stock due to its promising potential and strong leadership.
	2025-02-10	-2.32 %
Bristol Myers Squibb (BMY) stock fell by 2.32% due to a bleak outlook and concerns over increased operational costs impacting profitability. Bristol Myers Squibb (BMY) stock declined by 2.32% due to a generally negative outlook following disappointing fourth-quarter performance alongside sector pressures, as indicated by FMC's poor revenue forecast and its impact on market sentiment. Bristol Myers Squibb (BMY) stock declined by 2.32% amid a broader market reaction despite the company reporting positive earnings, likely influenced by macroeconomic concerns and investor sentiment overshadowing its financial results. Bristol-Myers Squibb (BMY) stock fell 2.32% despite an increase in its target price from Wells Fargo, likely due to mixed analyst ratings and overall market sentiment. Bristol Myers Squibb (BMY) stock dropped by 2.32% likely due to concerns surrounding the ongoing Medicare Drug Price Negotiation Program and its potential changes under the new Trump administration, which could adversely impact drug pricing dynamics and affect the company's business.
	2025-02-07	-0.99 %
Bristol Myers Squibb (BMY) stock declined by 0.99% likely due to concerns stemming from new research highlighting the aggressive nature of glioblastoma brain tumors and the role of immune cells in promoting their growth, which may affect investor confidence in related pharmaceutical treatments.
	2025-02-06	-3.84 %
Bristol-Myers Squibb (NYSE:BMY) shares fell by 3.84% amid a series of mixed earnings estimates and target price adjustments by analysts, indicating uncertainty and a predominantly "neutral" market sentiment towards the stock. Bristol Myers Squibb (BMY) stock fell 3.84% after the company reported adjusted earnings that surpassed analyst expectations, but the decline was likely influenced by other market factors or concerns about future performance despite strong sales figures.
	2025-02-05	+1 %
Bristol-Myers Squibb (BMY) stock increased by 1.0% due to a notable rise in institutional investor stakes, including Spire Wealth Management raising its holdings by 4.3%, indicating growing confidence among investors in the company's future performance. Bristol-Myers Squibb (BMY) stock rose by 1.0% as it approaches the announcement of its quarterly earnings, with expectations of strong earnings and a recent increase in its dividend payout reflecting positive investor sentiment amid various analyst upgrades.
	2025-02-04	-1.38 %
Bristol-Myers Squibb (BMY) stock fell by 1.38% following a downgrade in Q2 2025 earnings estimates from Zacks Research, which lowered its forecast from $1.94 to $1.90 per share. Bristol Myers Squibb (BMY) stock was down by 1.38% likely due to broader market movements and investor concerns surrounding revenue impacts from ongoing negotiations with Medicare regarding drug pricing, particularly for its blood thinner Eliquis, as Pfizer faces similar challenges and strives to manage declining revenues from patent expirations.
	2025-02-03	+1.7 %
Bristol-Myers Squibb's stock (BMY) rose 1.7% due to significant institutional investment activity, including firms like R Squared Ltd and FMR LLC increasing their stakes in the company, as well as positive earnings reports indicating strong revenue growth and an increase in dividends.
	2025-01-30	+0.15 %
Bristol Myers Squibb (BMY) stock rose by 0.15% likely due to positive earnings expectations, as indicated by its Earnings ESP of 0.43%, suggesting a good chance of exceeding analyst forecasts in the upcoming earnings report.
	2025-01-29	+0.49 %
Bristol-Myers Squibb (BMY) stock rose by 0.49% due to its strong performance in dividend growth, a solid track record of consecutive dividend payments, and a new partnership for CAR T cell therapy manufacturing that enhances its operational capacity and growth potential.
	2025-01-24	+0.9 %
Bristol-Myers Squibb (BMY) stock rose 0.9% following positive earnings projections from Cantor Fitzgerald, which forecasted an EPS of $6.82 for FY2025, alongside other analysts adjusting their price targets upwards and reporting strong recent financial performance exceeding market expectations.
	2025-01-23	+3.59 %
Bristol-Myers Squibb (BMY) stock rose by 3.59% following an upgrade in Q4 earnings estimates by William Blair, which indicated increased confidence in the company’s financial performance.
	2025-01-22	+0.09 %
Bristol-Myers Squibb (BMY) stock rose by 0.09% following increased institutional investment and positive quarterly earnings results that exceeded analyst expectations, as well as a recently announced dividend increase.
	2025-01-17	-0.16 %
Bristol-Myers Squibb (BMY) stock fell by 0.16% despite positive earnings estimates from analysts, as mixed ratings from other research firms and broader market factors may have contributed to the decline. The stock goes down due to a combination of mixed analyst ratings and market sentiments, despite a projected increase in earnings per share for upcoming quarters. Bristol Myers Squibb (BMY) stock dropped by 0.16% due to investor concerns and market dynamics affecting overall sentiment towards the pharmaceutical sector, which could include competition from other small-cap medical companies, such as Evotec and Citius Pharmaceuticals, that are showing stronger growth potential and analyst endorsements. Bristol-Myers Squibb (BMY) stock experienced a decline of 0.16% as institutional investor movements and insider trading activities may have contributed to uncertainty among investors.
	2025-01-15	+0.3 %
Bristol-Myers Squibb (BMY) stock rose 0.3% due to an upgrade by Leerink Partners, which increased its FY2024 earnings per share estimate and maintained a "Strong-Buy" rating, alongside positive earnings results that surpassed expectations. Bristol Myers Squibb (BMY) stock rose 0.3% due to its inclusion in the Schwab U.S. Dividend Equity ETF, which is popular among investors seeking dividend income, reflecting a broader trend towards dividend-paying stocks amid changing market conditions. Bristol-Myers Squibb (BMY) stock rose by 0.3% likely due to increased institutional investments, improved analyst ratings, and strong quarterly earnings that surpassed expectations. Bristol-Myers Squibb (BMY) stock rose 0.3% as institutional investors increased their stakes in the company, indicating renewed confidence in its financial performance after a strong quarterly earnings report and a dividend increase.
	2025-01-10	-1.73 %
Bristol-Myers Squibb (BMY) stock fell by 1.73% despite analysts raising their price targets for the company, which could be attributed to a combination of mixed investment ratings and the company's negative net margin of 15.30%.
	2025-01-06	+0.19 %
Bristol-Myers Squibb (BMY) stock increased by 0.19% due to significant institutional buying, including a 32.8% increase in holdings by Pensionfund Sabic and other hedge funds raising their stakes, suggesting strong investor confidence in the company's performance and future prospects. Bristol-Myers Squibb's stock increased by 0.19% due to significant investments from institutional investors and positive analyst ratings after a strong quarterly earnings report that exceeded expectations.
	2025-01-03	-0.39 %
Bristol-Myers Squibb (BMY) stock declined by 0.39%, likely due to fluctuations in options trading activity and ongoing fluctuations in analyst ratings, despite having reported better-than-expected quarterly earnings and recently increasing its dividend. Bristol-Myers Squibb (BMY) stock fell by 0.39% as several institutional investors increased their holdings in the company, indicating a mixed sentiment in the market amidst various research analysts' ratings. The downturn may be attributed to profit-taking by investors or fluctuations in market sentiment despite positive earnings results, as the stock has been experiencing volatility within a defined price range.
	2025-01-02	+0.41 %
Bristol-Myers Squibb (BMY) stock increased by 0.41% due to a rise in short interest, insider buying activity, and positive adjustments in institutional investors' holdings, reflecting growing confidence in the company's financial performance and its recent quarterly earnings beat.
	2024-12-27	-0.55 %
Bristol Myers Squibb (BMY) stock experienced a decline of 0.55% likely due to recent analysis suggesting it, despite being considered cheap, may not represent a strong value investment at this time, as not all appealing stocks are created equal.
	2024-12-19	-0.95 %
Bristol Myers Squibb (BMY) stock is down by 0.95% likely due to broader market trends or specific concerns affecting the biotechnology sector, including investor sentiment and company-specific news such as the completion of Banzai International's acquisition of OpenReel, which may have implications for their partnerships.
	2024-12-18	-1.41 %
Bristol Myers Squibb (BMY) stock decreased by 1.41% last night, potentially due to market sentiment as investors weigh clinical trial outcomes and partnerships, such as its collaboration with Perspective Therapeutics for cancer treatment.
	2024-12-17	+3.19 %
Bristol-Myers Squibb (BMY) stock rose 3.19% due to recent positive analyst upgrades, stronger-than-expected quarterly earnings, and significant institutional investment activity, leading to increased confidence in the company's market performance.
	2024-12-16	+0.16 %
Bristol-Myers Squibb (BMY) stock experienced a 0.16% increase, attributed to positive earnings results that exceeded analyst expectations and analysts upgrading their ratings on the stock, suggesting strong future performance. Bristol Myers Squibb (BMY) stock increased by 0.16% due to the announcement of a purchase of 300 shares by Jim Cramer's Charitable Trust, which boosts the stock's portfolio weighting and reflects investor confidence.
	2024-12-10	-1 %
Bristol Myers Squibb (BMY) stock declined by 1.0% due to market fluctuations, possibly influenced by broader economic factors or investor sentiments surrounding the pharmaceutical sector rather than any specific news about the company. Bristol Myers Squibb (BMY) stock has declined by 1.0%, potentially due to unfavorable comparisons with competing biopharmaceutical firms like BeiGene and Evoke Pharma, which are viewed more favorably by analysts in terms of growth potential and institutional debt.
	2024-12-09	-1.13 %
Bristol Myers Squibb (BMY) stock fell by 1.13% despite being recognized as a Top Socially Responsible Dividend Stock with a strong yield of 4.0%, likely due to broader market trends or sector-specific issues affecting pharmaceutical stocks.
	2024-12-02	+1.22 %
Bristol Myers Squibb (BMY) stock rose by 1.22% due to its diverse portfolio of medications and the anticipation of new programs nearing approval, which could boost its financial performance and appeal to investors.
	2024-11-27	+0.9 %
Bristol Myers Squibb (BMY) stock rose by 0.9%, potentially reflecting positive market sentiment or developments involving its collaborations and product pipelines, including partnerships with companies like Evotec and Sagimet Biosciences. Bristol Myers Squibb (BMY) stock rose by 0.9% due to positive sentiment stemming from its collaboration with Perspective Therapeutics, which is currently undergoing clinical trials that may enhance investor confidence in BMY's involvement in promising oncology therapies. Bristol Myers Squibb (BMY) stock rose 0.9% likely due to positive market sentiment and potential advancements in its clinical collaborations, particularly with Perspective Therapeutics, which focuses on oncology treatments. Bristol-Myers Squibb's stock (BMY) rose 0.9% due to its favorable prospects compared to Johnson & Johnson (JNJ), driven by market share gains from new drugs and a lower valuation multiple relative to its historical average.
	2024-11-26	-0.07 %
Bristol-Myers Squibb (BMY) stock experienced a slight decline of 0.07% amid varied institutional investments and insider trading activity, which may have contributed to investor uncertainty.
	2024-11-25	-0.15 %
Bristol-Myers Squibb (BMY) stock fell 0.15% as several hedge funds adjusted their holdings, but positive earnings reports suggest underlying strength in the company. The decline may be attributed to market fluctuations, investor profit-taking, and mixed analyst ratings despite the company's strong quarterly performance. Bristol-Myers Squibb (BMY) stock decreased by 0.15% likely due to broader market conditions or investor sentiment, despite plans to initiate a position in the stock.
	2024-11-22	+1.1 %
Bristol-Myers Squibb (BMY) stock rose by 1.1% following positive earnings results that exceeded analyst expectations and after several analysts updated their ratings and price targets for the stock, indicating a consensus recommendation of "Hold" with some upgrades to "Strong Buy." Bristol-Myers Squibb (BMY) stock rose 1.1% following upgraded earnings estimates from William Blair, which anticipates stronger EPS figures for upcoming quarters, alongside positive earnings results that exceeded consensus estimates and increased attention from institutional investors.
	2024-11-21	+0.6 %
Bristol-Myers Squibb's stock (BMY) rose by 0.6% following significant increases in positions by institutional investors, notably a 40% increase by Prospera Financial Services, and positive analyst ratings that have upgraded the stock, reflecting growing confidence in the company’s performance, particularly after better-than-expected quarterly earnings.
	2024-11-20	-0.6 %
Bristol Myers Squibb (BMY) stock dropped by 0.6% possibly due to market dynamics unrelated to its core activities, as the article primarily discusses comparisons between other small-cap medical companies, Perspective Therapeutics and Todos Medical, rather than providing specific reasons for BMY's decline.
	2024-11-19	+2.52 %
Bristol Myers Squibb (BMY) stock was up 2.52% last night, likely due to positive investor sentiment surrounding advancements in AI and potential industry innovations that could enhance operational efficiencies and revenue growth for healthcare companies. Bristol-Myers Squibb (BMY) stock rose by 2.52% following positive analyst ratings, including an upgrade from Leerink Partners to "outperform" and an increase in their price target, indicating growing investor confidence in the company's financial prospects after exceeding earnings expectations in its latest quarterly report.
	2024-11-18	+1.03 %
The article discusses the appointment of Dr. Gregg A. Pratt as Chief Regulatory and Quality Assurance Officer at Mind Medicine Inc., aiming to bolster the company's capabilities for upcoming Phase 3 studies in psychiatry. Bristol Myers Squibb (BMY) stock may have risen due to investor confidence stemming from the recent strategic acquisitions and advancements in regulatory affairs associated with MindMed, particularly given Dr. Pratt's experience in successfully guiding drug approvals.
	2024-11-15	-3.9 %
Bristol-Myers Squibb (BMY) stock fell by 3.9% after analysts at Leerink Partners reduced their earnings per share (EPS) forecasts for fiscal year 2026, indicating weaker-than-expected financial projections for the biopharmaceutical company.
	2024-11-12	-1.34 %
Bristol Myers Squibb (BMY) stock was down 1.34% following AbbVie's announcement that its investigational anti-psychotic drug emraclidine failed to meet primary endpoints in clinical trials, creating a competitive advantage for BMS with its acquisition of Karuna Therapeutics, which is progressing well with its own treatments.
	2024-11-11	+10.49 %
Bristol Myers Squibb (BMY) stock rose 10.49% following the disappointing trial results of AbbVie’s schizophrenia drug emraclidine, which gave a competitive edge to BMY's approved schizophrenia treatment, Cobenfy. Bristol Myers Squibb's stock surged 10.49% following the failure of AbbVie's experimental schizophrenia treatment in midstage studies, which likely increased investor confidence in Bristol Myers' own pipeline and market position. Bristol Myers Squibb (BMY) stock surged by 10.49% following the disappointing trial results of AbbVie's schizophrenia drug, which diminished competition in the market and bolstered confidence in Bristol's new treatment approved in September. The rise in BMY's stock can be attributed to AbbVie's setbacks with its schizophrenia drug, which have solidified Bristol's position and lead in the evolving market for schizophrenia treatments.
	2024-11-08	-1.04 %
Bristol-Myers Squibb (BMY) shares decreased by 1.04% amidst recent positive analyst ratings and insider buying, despite hitting a 52-week high of $56.78, likely due to market volatility and profit-taking after the stock's recent gains. Bristol Myers Squibb (BMY) stock declined by 1.04% recently, possibly due to investor reactions to competitive developments in the biopharmaceutical sector, including concerns about its partnerships with companies like Geron and Purple Biotech.
	2024-11-07	-1.03 %
Bristol Myers Squibb (BMY) stock recently experienced a decline of 1.03%, despite reporting better-than-expected Q3 results and raising its full-year outlook, potentially due to a marginal decrease in adjusted operating margin and ongoing volatility in stock performance relative to the broader market.
	2024-11-05	+0.9 %
Bristol-Myers Squibb (BMY) stock rose by 0.9% due to positive quarterly earnings results that exceeded analysts' expectations, increased institutional investment, and recent favorable analyst ratings.
	2024-11-04	+2.08 %
Bristol-Myers Squibb (BMY) stock rose 2.08% after BMO Capital Markets increased their price target for the company from $53.00 to $57.00, signaling positive sentiment in the market, especially following the company's better-than-expected earnings report and revenue growth.

1
500 / page